HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia

Trial Profile

HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Cytarabine (Primary) ; Mitoxantrone (Primary) ; Filgrastim
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Apr 2017 to 6 Mar 2019.
    • 14 Mar 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center: 9L11-8).
    • 14 Mar 2013 Status changed from not yet recruiting to recruiting as reported by University of Southern California Norris Comprehensive Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top